Cargando…
Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β-estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study
The present study aimed to evaluate the effects of 2 mg drospirenone (DRSP) and 1 mg 17β-estradiol (E2) hormone therapy (HT) in combination with rehabilitation therapy for postmenopausal women with Meniere's disease (MD). The combined drug hormone treatment was denoted as DRSP/E2. A total of 65...
Autores principales: | Grillo, Caterina Maria, Maiolino, Luigi, Rapisarda, Agnese Maria Chiara, Caruso, Giuseppe, Palermo, Gaia, Caruso, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383771/ https://www.ncbi.nlm.nih.gov/pubmed/34504557 http://dx.doi.org/10.3892/etm.2021.10537 |
Ejemplares similares
-
Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women
por: Park, Bo Ra, et al.
Publicado: (2017) -
How Does Contraceptive Use Affect Women’s Sexuality? A Novel Look at Sexual Acceptability
por: Caruso, Salvatore, et al.
Publicado: (2022) -
An Oral Contraceptive Containing Estetrol 15 MG and Drospirenone 3 MG Has Limited Effects on Endocrine and Metabolic Parameters
por: Klipping, Christine, et al.
Publicado: (2021) -
Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin
por: Bachmann, Gloria, et al.
Publicado: (2009) -
Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, S., et al.
Publicado: (2020)